Catalyst Venture Partners

Catalyst Venture Partners Ltd. is a venture capital and private equity firm established in 1999 and located in Bath, United Kingdom. The firm focuses on investing in private companies within the technology, media, health, environmental, and telecom sectors, targeting early-stage, growth capital, and mature investments. Catalyst typically invests between £0.5 million and £5 million, emphasizing the importance of a clear exit strategy for its portfolio. In addition to equity investments, the firm offers short-term financing and long-term loan options to support the growth of companies. Catalyst Venture Partners aims to collaborate with ambitious, entrepreneurial-led businesses, assisting them in recruiting management teams, developing growth strategies, and securing necessary funding.

Jim Marshall

Associate

Ian Mcanearney

Managing Director

Richard Turner

Chief Executive Officer

9 past transactions

Eloxx

Series C in 2017
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

iKoa

Venture Round in 2010
An early-stage semiconductor start-up company, iKoa® is dedicated to becoming a leader in enabling low-power, high-performance semiconductor products for consumer mobile devices in the mobile communications, entertainment, and personal computer markets. Founded by repeat entrepreneurs, iKoa surmounts the capability of today's semiconductor solutions by offering previously unattainable performance and new features for end-user products, at a very low power consumption. With iKoa's disruptive technology, semiconductor products can be designed with up to 4X more performance, more features, and 1/10th the power consumption of competing methods. iKoa has offices in Menlo Park, California (Silicon Valley) and engineering and development operations in Hyderabad, India.

EVRS

Series A in 2009
EVRS are a waste recycling company that have developed a unique technology for the recycling of non hazardous waste that diverts all waste from landfill. Their ‘Zero-Bury’ process has no discharges to air, to land or to water and has the capacity to turn cellulosic waste material into either ethanol or a high quality fibre which can be used as a basis for products such as construction boards.

Jentro Technologies

Series A in 2007
Jentro Technologies GmbH provides GPS-based mobile phone online navigation solutions for mobile communication companies in Europe. It offers Activepilot, an online navigation solution that provides complete fulfillment from hardware (design GPS-receivers) and client software (handset application) to back end service, billing, payment, and branding-cooperations; Bluetooth GPS receivers; and cable GPS receivers. The company also offers hardware, software, and operation services. Jentro Technologies GmbH was founded in 2003 and is based in Munich, Germany.

Yellowtag

Venture Round in 2003
Yellowtags are labels that contain an identity code, in the shape of a yellowtag.com e-mail address. The code and the customer’s own e-mail address are registered with the yellowtag.com website. If an item is found or handed in at a lost property office, the discoverer e-mails yellowtag, which then forwards the news to the owner, protecting the anonymity of the owner.

Proxima Therapeutics

Series E in 2002
Proxima Therapeutics develops radiation delivery systems for the treatment of solid cancerous tumors, with an initial focus on brain and breast cancer. Founded in 1996, the company’s marketed products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Proxima Therapeutics was acquired by Cytec Industries Inc. in 2005.

Proxima Therapeutics

Series D in 2001
Proxima Therapeutics develops radiation delivery systems for the treatment of solid cancerous tumors, with an initial focus on brain and breast cancer. Founded in 1996, the company’s marketed products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Proxima Therapeutics was acquired by Cytec Industries Inc. in 2005.

Express Digital Graphics

Series B in 2000
Express Digital's PhotoReflect.com is a truly amazing way to make money without even trying. I take and upload the pictures, go out and do another session, and by the time I'm back in the studio, I have already received orders that need to be fulfilled. Now that's a no hassle way to make money. Rather than spend an hour with only one customer, your customers can go online and order anytime, day or night. It's like having an extra salesman that you don't have to pay for!

Express Digital Graphics

Series A in 1999
Express Digital's PhotoReflect.com is a truly amazing way to make money without even trying. I take and upload the pictures, go out and do another session, and by the time I'm back in the studio, I have already received orders that need to be fulfilled. Now that's a no hassle way to make money. Rather than spend an hour with only one customer, your customers can go online and order anytime, day or night. It's like having an extra salesman that you don't have to pay for!
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.